GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Interest Coverage

VRCDF (Verici Dx) Interest Coverage : 0 (At Loss) (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Verici Dx's Operating Income for the six months ended in Jun. 2024 was $-1.45 Mil. Verici Dx's Interest Expense for the six months ended in Jun. 2024 was $-0.01 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Verici Dx's Interest Coverage or its related term are showing as below:


VRCDF's Interest Coverage is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 12.26
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Verici Dx Interest Coverage Historical Data

The historical data trend for Verici Dx's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Verici Dx Interest Coverage Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Interest Coverage
No Debt No Debt - -

Verici Dx Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Interest Coverage Get a 7-Day Free Trial No Debt - - - -

Competitive Comparison of Verici Dx's Interest Coverage

For the Diagnostics & Research subindustry, Verici Dx's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verici Dx's Interest Coverage Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Verici Dx's Interest Coverage falls into.


;
;

Verici Dx Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Verici Dx's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Verici Dx's Interest Expense was $-0.03 Mil. Its Operating Income was $-8.87 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.38 Mil.

Verici Dx did not have earnings to cover the interest expense.

Verici Dx's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

Here, for the six months ended in Jun. 2024, Verici Dx's Interest Expense was $-0.01 Mil. Its Operating Income was $-1.45 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.27 Mil.

Verici Dx did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Verici Dx  (OTCPK:VRCDF) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Verici Dx Interest Coverage Related Terms

Thank you for viewing the detailed overview of Verici Dx's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Verici Dx Business Description

Traded in Other Exchanges
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines